Excelimmune, Inc. is a biopharmaceutical company specializing in the development of fully human recombinant polyclonal antibodies for therapeutic use. This next generation technology is applicable in the treatment of infectious diseases, as well as protein diseases and cancer. Human recombinant polyclonal antibodies harness the diversity and effectiveness of the collective human immune system.

The Center for Molecular Therapeutics is actively investigating better ways to match individual cancer patients with particular targeted drug therapies in order to maximize the likelihood of a clinical responseThe broad objective of this Center's research is to identify molecular genetic features of a tumor that predict responsiveness to the various small molecule targeted therapies that have either recently been developed or are in early clinical development. Some of these drugs have been found to be highly effective in inducing remissions in a fraction of treated patients, and it is becoming increasingly clear that molecular features, or "biomarkers," that correlate with drug-responsiveness can be identified in these patients. Such findings can be of great value in designing clinical trials of new cancer drugs as well as in optimizing the clinical benefit of approved drugs.